<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753050</url>
  </required_header>
  <id_info>
    <org_study_id>HipHop</org_study_id>
    <secondary_id>EA1/315/12</secondary_id>
    <nct_id>NCT01753050</nct_id>
  </id_info>
  <brief_title>HIP Surgery - Hemodynamic Optimization Project</brief_title>
  <acronym>HipHop</acronym>
  <official_title>A Quality Improvement Project for Goal-directed Intraoperative Hemodynamic Optimization in Patients Redo Hip Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several studies have demonstrated that goal-directed fluid therapy during high- risk-surgery
      reduces morbidity and length of hospital stay. This quality improvement is design to
      evaluate the implementation of an intraoperative goal-directed therapy, using a pulse
      contour analysis monitor to optimize the stroke volume, in patients undergoing
      redo-hip-surgery. The primary combined endpoints will be the incidence of postoperative
      complications and the secondary endpoints will be the decrease of hospital length of stay,
      length of ICU stay and hospital postoperative mortality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>30days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital and ICU stay</measure>
    <time_frame>30days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Redo Hip Surgery</condition>
  <arm_group>
    <arm_group_label>Stroke volume monitoring</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Stroke volume monitoring in all patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stroke volume monitoring</intervention_name>
    <description>Pulse contour stroke volume monitoring</description>
    <arm_group_label>Stroke volume monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing redo hip surgery

          -  age above 18 years

          -  signed informed consent

        Exclusion Criteria:

          -  urgent or emergency surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Sander, MD</last_name>
    <phone>+49 30 450 531</phone>
    <phone_ext>012</phone_ext>
    <email>Michael.Sander@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Krämer, MD</last_name>
    <phone>+4930450531</phone>
    <phone_ext>052</phone_ext>
    <email>Michael.Kraemer@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive Care Medicine Campus Charité Mitte / Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sander, MD</last_name>
      <phone>+4930450531</phone>
      <phone_ext>052</phone_ext>
      <email>Michael.Sander@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Michael Krämer, MD</last_name>
      <phone>+4930450531</phone>
      <phone_ext>012</phone_ext>
      <email>Michael.Kraemer@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Sander, MD Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 8, 2013</lastchanged_date>
  <firstreceived_date>December 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Michael Sander</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
